PATENT CLAIM ANALYSIS

Application Number: 15751472
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

Claim (Index 40):
A method according to  claim 39 , wherein said gene locus is involved into the expression of PD1 or CTLA-4 genes.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 88.0
- Lexical Diversity: 1.21569
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15302450', '15126540', '14952448', '15301686', '14403937']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7560815904972551
- 35 USC 102 Novelty (BERT): 0.5491517994538292
- Combined Prediction Score: 0.7353886113929125
- Mean Citation Score: 368.64456000000007
- Max Citation Score: 405.39853
- Similarity Product: 260.7340587846619

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test